Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes.

Shiseki M, Ishii M, Okada M, Ohwashi M, Wang YH, Osanai S, Yoshinaga K, Mori N, Motoji T, Tanaka J.

Leuk Res. 2019 Sep;84:106175. doi: 10.1016/j.leukres.2019.106175. Epub 2019 Jun 28.

PMID:
31299412
2.

Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.

Wang YH, Imai Y, Shiseki M, Tanaka J, Motoji T.

Leuk Res. 2018 Apr;67:99-108. doi: 10.1016/j.leukres.2018.01.020. Epub 2018 Jan 31.

PMID:
29482174
3.

Tumor suppressor gene methylation on the short arm of chromosome 1 in chronic myelogenous leukemia.

Mori N, Ohwashi-Miyazaki M, Yoshinaga K, Okada M, Shiseki M, Motoji T, Tanaka J.

Eur J Haematol. 2017 May;98(5):467-477. doi: 10.1111/ejh.12857. Epub 2017 Mar 1.

PMID:
28129457
4.

Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.

Imai Y, Ohta E, Takeda S, Sunamura S, Ishibashi M, Tamura H, Wang YH, Deguchi A, Tanaka J, Maru Y, Motoji T.

JCI Insight. 2016 Apr 21;1(5):e85061. doi: 10.1172/jci.insight.85061.

5.

Impact of Elevated Hemoglobin and Serum Protein on Vasovagal Reaction from Blood Donation.

Odajima T, Takanashi M, Sugimori H, Tanba T, Yoshinaga K, Motoji T, Munakata M, Nakajima K, Minami M.

PLoS One. 2016 Feb 19;11(2):e0148854. doi: 10.1371/journal.pone.0148854. eCollection 2016.

6.

Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.

Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J.

Leuk Lymphoma. 2016 Sep;57(9):2204-7. doi: 10.3109/10428194.2015.1126589. Epub 2015 Dec 24. No abstract available.

PMID:
26699798
7.

Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.

Toya T, Nannya Y, Hangaishi A, Shiseki M, Shimoyama T, Sakamaki H, Motoji T, Usuki K, Nakamura F, Kurokawa M.

Leuk Lymphoma. 2016;57(4):961-4. doi: 10.3109/10428194.2015.1083097. Epub 2015 Dec 23. No abstract available.

PMID:
26366623
8.

Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32).

Shiseki M, Masuda A, Yoshinaga K, Mori N, Okada M, Motoji T, Tanaka J.

Int J Hematol. 2015 Nov;102(5):633-8. doi: 10.1007/s12185-015-1823-z. Epub 2015 Jun 27.

PMID:
26115875
9.

Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia.

Kazama H, Teramura M, Kurihara S, Yoshinaga K, Kato T, Motoji T.

Br J Haematol. 2014 Sep;166(5):720-8. doi: 10.1111/bjh.12954. Epub 2014 May 26.

PMID:
24862795
10.

Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy.

Mitsuhashi K, Masuda A, Wang YH, Shiseki M, Motoji T.

Int J Hematol. 2014 Jul;100(1):88-95. doi: 10.1007/s12185-014-1593-z. Epub 2014 May 13.

PMID:
24820636
11.

L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.

Mori N, Ohwashi M, Yoshinaga K, Mitsuhashi K, Tanaka N, Teramura M, Okada M, Shiseki M, Tanaka J, Motoji T.

PLoS One. 2013 Nov 5;8(11):e80088. doi: 10.1371/journal.pone.0080088. eCollection 2013.

12.

Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source.

Shiozaki H, Yoshinaga K, Kondo T, Imai Y, Shiseki M, Mori N, Teramura M, Motoji T.

Bone Marrow Transplant. 2014 Jan;49(1):102-9. doi: 10.1038/bmt.2013.127. Epub 2013 Sep 9. Review.

PMID:
24013690
13.

[Analysis of molecular mechanism involved in development of acute myeloid leukemia].

Katsumi S, Kawauchi K, Ozaki K, Shimizu S, Kimura T, Motoji T, Yamada O.

Gan To Kagaku Ryoho. 2013 Apr;40(4):471-7. Japanese.

PMID:
23848014
14.

Positron emission tomography revealed diffuse involvement of the lower legs and occult extracutaneous lesions in subcutaneous panniculitis-like T-cell lymphoma.

Mitsuhashi K, Momose M, Masuda A, Tsunemi Y, Motoji T.

Clin Nucl Med. 2013 Mar;38(3):209-11. doi: 10.1097/RLU.0b013e31827087ca.

PMID:
23354029
15.

[Usefulness of (18)F-FDG PET/CT for detecting lesions in patients with POEMS syndrome].

Tanaka N, Yoshinaga K, Asano C, Kazama H, Okamura T, Shiseki M, Mori N, Teramura M, Kusakabe K, Sakai S, Motoji T.

Rinsho Ketsueki. 2012 Dec;53(12):2013-7. Japanese.

PMID:
23318968
16.

[Long-term remission after nonmyeloablative allogeneic bone marrow transplantation in a relapsed Hodgkin lymphoma patient with CNS involvement].

Shimura H, Imai Y, Ishiyama M, Yoshinaga K, Shiseki M, Mori N, Teramura M, Motoji T.

Rinsho Ketsueki. 2012 Dec;53(12):1991-6. Review. Japanese.

PMID:
23318964
17.

[Epidemiology of hematological malignancies around the world].

Motoji T.

Nihon Rinsho. 2012 Apr;70 Suppl 2:19-25. Japanese. No abstract available.

PMID:
23133922
18.

Long-term remission of primary bone marrow diffuse large B-cell lymphoma treated with high-dose chemotherapy rescued by in vivo rituximab-purged autologous stem cells.

Kazama H, Teramura M, Yoshinaga K, Masuda A, Motoji T.

Case Rep Med. 2012;2012:957063. doi: 10.1155/2012/957063. Epub 2012 Oct 16.

19.

Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.

Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F.

Leuk Lymphoma. 2013 Jul;54(7):1450-8. doi: 10.3109/10428194.2012.745074. Epub 2012 Nov 26.

PMID:
23110324
20.

Overexpression of lung resistance-related protein and P-glycoprotein and response to induction chemotherapy in acute myelogenous leukemia.

Tsuji K, Wang YH, Takanashi M, Odajima T, Lee GA, Sugimori H, Motoji T.

Hematol Rep. 2012 Jul 11;4(3):e18. doi: 10.4081/hr.2012.e18. Epub 2012 Oct 1.

21.

Facial-oropharyngeal Kaposi sarcoma in a HIV-seropositive man.

Hirai Y, Yoshihara T, Motoji T, Totsuka K.

Intern Med. 2012;51(20):2989-90. Epub 2012 Oct 15. No abstract available.

22.

Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis.

Shimura H, Imai Y, Ieko M, Shiseki M, Mori N, Teramura M, Motoji T.

Ann Hematol. 2013 Jan;92(1):143-4. doi: 10.1007/s00277-012-1532-0. Epub 2012 Aug 5. No abstract available.

PMID:
22864763
23.

Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.

Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, Seshimo A, Motoji T.

Br J Haematol. 2012 Sep;158(6):798-800. doi: 10.1111/j.1365-2141.2012.09220.x. Epub 2012 Jul 3. No abstract available.

PMID:
22758388
24.

Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study.

Ogata K, Kakumoto K, Matsuda A, Tohyama K, Tamura H, Ueda Y, Kurokawa M, Takeuchi J, Shibayama H, Emi N, Motoji T, Miyazaki Y, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F.

Leuk Res. 2012 Oct;36(10):1229-36. doi: 10.1016/j.leukres.2012.05.006. Epub 2012 Jun 7.

PMID:
22682984
25.

Risk factor analysis of vasovagal reaction from blood donation.

Takanashi M, Odajima T, Aota S, Sudoh M, Yamaga Y, Ono Y, Yoshinaga K, Motoji T, Matsuzaki K, Satake M, Sugimori H, Nakajima K.

Transfus Apher Sci. 2012 Dec;47(3):319-25. doi: 10.1016/j.transci.2012.04.002. Epub 2012 May 28.

PMID:
22647682
26.

Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies.

Okada M, Suto Y, Hirai M, Shiseki M, Usami A, Okajima K, Teramura M, Mori N, Motoji T.

Cancer Genet. 2012 Jan-Feb;205(1-2):18-24. doi: 10.1016/j.cancergen.2011.12.002.

PMID:
22429594
27.

Acquired hemophilia A in a patient with essential thrombocythemia.

Mori N, Totsuka K, Ishimori N, Yoshinaga K, Teramura M, Noguchi S, Oda H, Motoji T.

Acta Haematol. 2012;127(3):170-2. doi: 10.1159/000335132. Epub 2012 Feb 1.

PMID:
22301942
28.

Aberrant methylation and decreased expression of the RIZ1 gene are frequent in adult acute lymphoblastic leukemia of T-cell phenotype.

Shimura H, Mori N, Wang YH, Okada M, Motoji T.

Leuk Lymphoma. 2012 Aug;53(8):1599-609. doi: 10.3109/10428194.2012.663086. Epub 2012 Mar 13.

PMID:
22300346
29.

Development of diffuse large B-cell lymphoma in a patient with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms.

Shiseki M, Masuda A, Watanabe N, Fujii M, Kimura T, Yoshinaga K, Mori N, Teramura M, Motoji T.

Hematol Rep. 2011 Aug 31;3(2):e10. doi: 10.4081/hr.2011.e10. Epub 2011 Aug 30.

30.

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.

Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K.

Haematologica. 2012 Jun;97(6):903-6. doi: 10.3324/haematol.2011.056853. Epub 2011 Dec 16.

31.

[Angioimmunoblastic T-cell lymphoma with marked polyclonal plasmacytosis in peripheral blood and bone marrow mimicking plasma cell leukemia].

Mitsuhashi K, Shiseki M, Ishiyama M, Kondo T, Kazama H, Yasunami T, Okamura T, Yoshinaga K, Mori N, Teramura M, Masuda A, Motoji T.

Rinsho Ketsueki. 2011 Jul;52(7):563-9. Japanese.

PMID:
21821991
32.

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.

Kobayashi Y, Sakamaki H, Fujisawa S, Ando K, Yamamoto K, Okada M, Ishizawa K, Nagai T, Miyawaki S, Motoji T, Usui N, Iida S, Taniwaki M, Uoshima N, Seriu T, Ohno R.

Int J Hematol. 2011 Jun;93(6):745-749. doi: 10.1007/s12185-011-0864-1. Epub 2011 May 20.

PMID:
21594763
33.

Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells.

Tanaka N, Wang YH, Shiseki M, Takanashi M, Motoji T.

Leuk Res. 2011 Sep;35(9):1219-25. doi: 10.1016/j.leukres.2011.04.005. Epub 2011 May 7.

PMID:
21550659
34.

Absence of mutations on the SNF5 gene in hematological neoplasms with chromosome 22 abnormalities.

Mori N, Inoue K, Okada M, Motoji T.

Acta Haematol. 2011;126(2):69-75. doi: 10.1159/000324932. Epub 2011 Apr 13.

PMID:
21494030
35.

Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review.

Hirai Y, Ainoda Y, Shoji T, Fujita T, Yoshinaga K, Shiseki M, Mori N, Teramura M, Totsuka K, Motoji T.

Mycopathologia. 2011 Sep;172(3):227-32. doi: 10.1007/s11046-011-9423-9. Epub 2011 Apr 7.

PMID:
21472389
36.

Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.

Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, Mitsuishi T, Akiyama M, Yamada H, Kawauchi K, Matsuoka R.

Cell Signal. 2011 Jul;23(7):1119-27. doi: 10.1016/j.cellsig.2011.02.005. Epub 2011 Feb 26.

PMID:
21356308
37.

Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, Omachi K, Hotta T.

Eur J Haematol. 2011 Feb;86(2):117-23. doi: 10.1111/j.1600-0609.2010.01552.x. Epub 2010 Dec 29.

PMID:
21070370
38.

[Treatment of myeloproliferative neoplasms].

Motoji T.

Rinsho Ketsueki. 2010 Oct;51(10):1428-36. Review. Japanese. No abstract available.

PMID:
20962476
39.

Successful salvage treatment of blastic natural killer cell lymphoma with methotrexate.

Kobayashi S, Teramura M, Arai M, Masuda A, Mizoguchi H, Motoji T.

Int J Hematol. 2010 Nov;92(4):634-7. doi: 10.1007/s12185-010-0660-3. Epub 2010 Oct 9.

PMID:
20936384
40.

Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia.

Mori N, Yoshinaga K, Tomita K, Ohwashi M, Kondoh T, Shimura H, Wang YH, Shiseki M, Okada M, Motoji T.

Leuk Res. 2011 Apr;35(4):516-21. doi: 10.1016/j.leukres.2010.08.002. Epub 2010 Sep 9.

PMID:
20828818
41.

Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan.

Nagai T, Takeuchi J, Dobashi N, Kanakura Y, Taniguchi S, Ezaki K, Nakaseko C, Hiraoka A, Okada M, Miyazaki Y, Motoji T, Higashihara M, Tsukamoto N, Kiyoi H, Nakao S, Shinagawa K, Ohno R, Naoe T, Ohnishi K, Usui N.

Int J Hematol. 2010 Jul;92(1):111-7. doi: 10.1007/s12185-010-0621-x. Epub 2010 Jun 25.

PMID:
20577839
42.

[Factors affecting the response of thalidomide therapy for patients with multiple myeloma].

Agata M, Sameshima Y, Oda T, Kondo T, Ishiyama M, Yasunami T, Kazama H, Okamura T, Yoshinaga K, Shiseki M, Mori N, Yamada O, Sagawa K, Teramura M, Motoji T.

Rinsho Ketsueki. 2010 Mar;51(3):189-95. Japanese.

PMID:
20379113
43.

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.

Sakamaki H, Ishizawa KI, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N, Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T, Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S, Seriu T, Ohno R.

Int J Hematol. 2009 Apr;89(3):332-341. doi: 10.1007/s12185-009-0260-2. Epub 2009 Mar 5.

PMID:
19263190
44.

Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.

Wang YH, Takanashi M, Tsuji K, Tanaka N, Shiseki M, Mori N, Motoji T.

Leuk Res. 2009 Jul;33(7):902-7. doi: 10.1016/j.leukres.2008.12.012. Epub 2009 Jan 30.

PMID:
19185918
45.

Leukemic cells with increased telomerase activity exhibit resistance to imatinib.

Yamada O, Kawauchi K, Akiyama M, Ozaki K, Motoji T, Adachi T, Aikawa E.

Leuk Lymphoma. 2008 Jun;49(6):1168-77. doi: 10.1080/10428190802043861.

PMID:
18569639
46.

JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.

Yoshinaga K, Mori N, Wang YH, Tomita K, Shiseki M, Motoji T.

Int J Hematol. 2008 Jul;88(1):82-87. doi: 10.1007/s12185-008-0103-6. Epub 2008 Jun 6.

PMID:
18528646
47.

Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation.

Kitagawa Y, Sameshima Y, Shiozaki H, Ogawa S, Masuda A, Mori SI, Teramura M, Masuda M, Kameoka S, Motoji T.

Int J Hematol. 2008 May;87(4):410-413. doi: 10.1007/s12185-008-0067-6.

PMID:
18365139
48.

Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, Okada M, Mori N, Motoji T.

Leuk Lymphoma. 2007 Nov;48(11):2141-4.

PMID:
17990177
49.

[Treatment of acute myelogenous leukemia and strategies to overcome multidrug resistance].

Motoji T.

Rinsho Ketsueki. 2007 Oct;48(10):1300-11. Review. Japanese. No abstract available.

PMID:
17933114
50.

A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response.

Ishikawa T, Tohyama K, Nakao S, Yoshida Y, Teramura M, Motoji T, Takatoku M, Kurokawa M, Mitani K, Uchiyama T, Omine M.

Int J Hematol. 2007 Aug;86(2):150-7.

PMID:
17875530

Supplemental Content

Loading ...
Support Center